Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07596979

Ginger in the Modulation of Inflammatory Cytokines and Oxidative Stress in Patients With Coronary Artery Disease

The study aims to evaluate the effect of ginger supplementation on inflammatory cytokines and markers of oxidative stress in patients with Coronary Artery Disease (CAD). A longitudinal double-blind randomized clinical trial will be carried out, involving CAD participants for two months.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Coronary Artery Disease (CAD) Arterial Occlusive Diseases Arteriosclerosis Cardiovascular Diseases Coronary Artery Disease Coronary Disease Heart Diseases Inflammation Myocardial Ischemia Oxidative Stress Pathologic Processes Pathological Conditions, Signs and Symptoms Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Denise mafra

Rio de Janeiro, 24220-900, Brazil

Location contact

Ludmila Cardozo

CONTACT

[email protected]

About this study

Ginger (Zingiber officinale Roscoe) contains phenolic compounds, such as gingerols, shogaols, and zingiberene, recognized for their antioxidant and anti-inflammatory properties, and may act as an adjuvant strategy in the prevention and management of CAD. However, there are no studies in CAD patients evaluating these data.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Both sexes
  • Over 18 years of age;
  • Diagnosed with Coronary Artery Disease: confirmed by coronary angiography, coronary computed tomography angiography, or functional testing with ischemic load);
  • Participants who are asymptomatic or have angina limited to functional class III will be considered;
  • Patients who have already undergone coronary revascularization and angioplasty may participate;
  • the last acute coronary event must have occurred more than one year ago.

Exclusion criteria

  • Unstable Coronary Artery Disease;
  • Pre-operative coronary artery bypass grafting or awaiting elective angioplasty;
  • Unstable angina;
  • NYHA functional class III or higher;
  • Advanced chronic kidney disease (creatinine clearance < 30 ml/min/1.73 m²);
  • Individuals with autoimmune diseases.

Treatment and study plan

Ginger

Dietary Supplement

Participants will receive 2 capsules per day, providing the ginger extract daily, at a dosage of 500mg.

Other names: ginger extract

Placebo

Dietary Supplement

The placebo group will receive the same amount of 500mg placebo, at the same time, containing corn starch.

Primary outcomes

  1. Change of inflammatory status in the participants

    Time frame: Baseline and 8 weeks

    Get blood samples to evaluate the supplementation effects in inflammatory biomarkers: interleukin 6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), C-reactive protein (CRP).

Study contacts

Contact information is provided by the study sponsor or research team.

Denise Mafra

CONTACT

[email protected]

+5521985683003

Ludmila Cardozo

CONTACT

[email protected]

+5521987333185

Sponsors and collaborators

Lead sponsor

Universidade Federal Fluminense

Other

Collaborators

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Rio de Janeiro State Research Supporting Foundation (FAPERJ)

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2028
First posted
May 19, 2026
Registry last updated
May 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.